Blood Adv. 2025 Jun 25:bloodadvances.2025017058. doi: 10.1182/bloodadvances.2025017058. Online ahead of print. ABSTRACT We conducted this systematic review to evaluate outcomes of thrombolysis followed by anticoagulation …
Cereb Cortex. 2025 Jun 4;35(6):bhaf155. doi: 10.1093/cercor/bhaf155. ABSTRACT Children with attention-deficit hyperactivity disorder exhibit multidimensional abnormalities of brain function, and the identification of key brain …
Crit Rev Oncog. 2025;30(2):13-21. doi: 10.1615/CritRevOncog.2025058176. ABSTRACT Acute lymphoblastic leukemia (ALL) is a common pediatric cancer marked by uncontrolled proliferation of lymphoblasts, primarily affecting children …
JAMA Netw Open. 2025 Jun 2;8(6):e2517291. doi: 10.1001/jamanetworkopen.2025.17291. ABSTRACT IMPORTANCE: While epinephrine is commonly administered in children with out-of-hospital cardiac arrest (OHCA) via an intraosseous …
Multimed Man Cardiothorac Surg. 2025 Jun 25;2025. doi: 10.1510/mmcts.2024.136. ABSTRACT We present a 12-year-old patient with periosteal osteosarcoma and bilateral pulmonary arterial tumour thrombi. The …
J Natl Cancer Inst. 2025 Jun 25:djaf150. doi: 10.1093/jnci/djaf150. Online ahead of print. ABSTRACT One in twelve malignancies is diagnosed in a young adult between …
JAMA Netw Open. 2025 Jun 2;8(6):e2517360. doi: 10.1001/jamanetworkopen.2025.17360. ABSTRACT IMPORTANCE: Fetal growth restriction (FGR) is associated with adverse neurodevelopmental outcomes. However, the delineation of neurodevelopmental …
JAMA Psychiatry. 2025 Jun 25. doi: 10.1001/jamapsychiatry.2025.1281. Online ahead of print. ABSTRACT IMPORTANCE: The prescription of attention-deficit/hyperactivity disorder (ADHD) medications has risen substantially in many …
JAMA Psychiatry. 2025 Jun 25. doi: 10.1001/jamapsychiatry.2025.1258. Online ahead of print. ABSTRACT IMPORTANCE: Functional brain networks are associated with both behavior and genetic factors. To …
Clin Pharmacokinet. 2025 Jun 25. doi: 10.1007/s40262-025-01536-x. Online ahead of print. ABSTRACT BACKGROUND AND OBJECTIVE: Eculizumab is an expensive therapeutic monoclonal antibody inhibiting complement C5 …
